Abacavir has no prothrombotic effect on platelets in vitro.

Autor:	Diallo YL; INSERM U1148, Hôpital Bichat, Paris, France., Ollivier V; INSERM U1148, Hôpital Bichat, Paris, France., Joly V; Service des Maladies Infectieuses et tropicales, Groupe Hospitalier Paris Nord Val de Seine, AP-HP, Hôpital Bichat, Paris, France.; Université Paris-Diderot, Sorbonne Paris-Cité, Paris, France., Faille D; INSERM U1148, Hôpital Bichat, Paris, France.; Université Paris-Diderot, Sorbonne Paris-Cité, Paris, France.; Département d'hématologie, Groupe Hospitalier Paris Nord Val de Seine, AP-HP, Hôpital Bichat, Paris, France., Catalano G; Service des Maladies Infectieuses et tropicales, Groupe Hospitalier Paris Nord Val de Seine, AP-HP, Hôpital Bichat, Paris, France.; Université Paris-Diderot, Sorbonne Paris-Cité, Paris, France., Jandrot-Perrus M; INSERM U1148, Hôpital Bichat, Paris, France.; Université Paris-Diderot, Sorbonne Paris-Cité, Paris, France.; Département d'hématologie, Groupe Hospitalier Paris Nord Val de Seine, AP-HP, Hôpital Bichat, Paris, France., Rauch A; Institut d'Hématologie Transfusion, CHU Lille, F-59000 Lille, France., Yeni P; Service des Maladies Infectieuses et tropicales, Groupe Hospitalier Paris Nord Val de Seine, AP-HP, Hôpital Bichat, Paris, France.; Université Paris-Diderot, Sorbonne Paris-Cité, Paris, France., Ajzenberg N; INSERM U1148, Hôpital Bichat, Paris, France nadine.ajzenberg@aphp.fr.; Université Paris-Diderot, Sorbonne Paris-Cité, Paris, France.; Département d'hématologie, Groupe Hospitalier Paris Nord Val de Seine, AP-HP, Hôpital Bichat, Paris, France.
Jazyk:	angličtina
Zdroj:	The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2016 Dec; Vol. 71 (12), pp. 3506-3509. Date of Electronic Publication: 2016 Aug 11.
DOI:	10.1093/jac/dkw303
Abstrakt:	Objectives: HIV patients exposed to abacavir have an increased risk of myocardial infarction, with contradictory results in the literature. The aim of our study was to determine whether abacavir has a direct effect on platelet activation and aggregation using platelets from healthy donors and from HIV-infected patients under therapy with an undetectable viral load. Methods: Platelet-rich plasma (PRP) or whole blood from healthy donors was treated with abacavir (5 or 10 μg/mL) or its active metabolite carbovir diphosphate. Experiments were also performed using blood of HIV-infected patients (n = 10) with an undetectable viral load. Platelet aggregation was performed on PRP by turbidimetry and under high shear conditions at 4000 s -1 . Platelet procoagulant potential was analysed by measuring thrombin generation by thrombinography. Results: Abacavir and carbovir diphosphate significantly increased the aggregation of platelets from healthy donors induced by collagen at 2 μg/mL (P = 0.002), but not at 0.5 μg/mL. No effect of abacavir or carbovir diphosphate was observed on platelet aggregation induced by other physiological agonists or by high shear stress, or on thrombin generation. Pretreatment of blood from HIV-infected patients with abacavir produced similar results. Conclusions: Our results suggest that abacavir does not significantly influence platelet activation in vitro when incubated with platelets from healthy donors or from HIV-infected patients. It is, however, not excluded that a synergistic effect with other drugs could promote platelet activation and thereby play a role in the pathogenesis of myocardial infarction. (© The Author 2016. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu